{"analyses":[{"ciLowerLimit":"0.79","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"7.32","estimateComment":"An odds ratio \\>1 favoured olaparib","groupDescription":"Analysis of olaparib 200 or 400 (n=64) versus liposomal doxorubicin (n=33).","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.1291","pValueComment":"2-sided p-value","paramType":"Odds Ratio (OR)","paramValue":"2.27","statisticalComment":"Analysis was performed using logistic regression with factors for treatment, BRCA status and platinum sensitivity.","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.55","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"7.01","estimateComment":"An odds ratio \\>1 favoured olaparib.","groupDescription":"Analysis of olaparib 200 (n=32) versus liposomal doxorubicin (n=33).","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.3131","pValueComment":"2-sided p-value","paramType":"Odds Ratio (OR)","paramValue":"1.90","statisticalComment":"Analysis was performed using logistic regression with factors for treatment, BRCA status and platinum sensitivity.","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.81","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"9.76","estimateComment":"An odds ratio \\>1 favoured olaparib","groupDescription":"Analysis of olaparib 400 (n=32) versus liposomal doxorubicin (n=33).","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.1079","paramType":"Odds Ratio (OR)","paramValue":"2.69","statisticalComment":"The analysis was performed using logistic regression with factors for treatment, BRCA status and platinum sensitivity.","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}]}],"title":"Number of Partial responders"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"33"}],"units":"Participants"}],"description":"ORR was defined according to RECIST. Complete response (CR) or partial response - (PR)- 30% decrease Patients with a best RECIST response of CR or PR had to have a confirmed response at least 28 days later.","groups":[{"description":"Olaparib (AZD2281) 200 mg oral capsules twice daily","id":"OG000","title":"Olaparib 200 mg bd"},{"description":"Olaparib (AZD2281) 400 mg oral capsules twice daily","id":"OG001","title":"Olaparib 400 mg bd"},{"description":"Liposomal doxorubicin 50 mg/m2 intravenously every 4 weeks","id":"OG002","title":"Liposomal Doxorubicin"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}